Bavarian Nordic Stock: Price BAVAc.DXE & About

TRADE NOW

[[ data.name ]]

[[ data.ticker ]]

[[ data.price ]] [[ data.change ]] ([[ data.changePercent ]]%)

Low: [[ data.low ]]

High: [[ data.high ]]

Sell
[[ data.bid ]] [[ data.spreadText ]] Buy
[[ data.ask ]]

About

History

Competitors

About

History

Competitors

Bavarian Nordic AS (BAVAc.DXE) is a biotechnology company based in Denmark. It specializes in the research, development, and production of vaccines and immunotherapies for infectious diseases and cancer. Founded in 1994, the company has a strong focus on innovative vaccine technology and has established itself as a leading player in the field.

Bavarian Nordic went public in 2005 and is listed on the OMX Nordic Exchange Copenhagen. With a current market cap of 16.59 billion DKK, the company has experienced growth and success in the pharmaceutical industry. It continues to advance its pipeline of vaccine candidates and collaborate with partners globally to address critical public health needs.

Over the past five years, the share price of Bavarian Nordic has experienced fluctuations driven by various factors, including clinical trial results, regulatory approvals, and market sentiment.

During the past five years, the stock has seen its highest price reach a peak of 411.0 DKK in August 2022 and its lowest price dip to a low of 93.1 DKK in December 2018. Throughout its history, the company has achieved notable milestones, such as successfully completing clinical trials for its vaccine candidates and obtaining regulatory approvals for commercialization.

These achievements have had an impact on the company's share price, leading to notable fluctuations. It's worth noting that the stock market is influenced by a multitude of factors, including economic conditions, industry trends, and investor sentiment. Therefore, the share price of Bavarian Nordic and any curiosities associated with it should be considered within the broader context of the company's operations and the overall market conditions at any given time.

Before trading Bavarian Nordic AS stock, it is worth considering the company's competitors in the biopharmaceutical industry. While the specific competitors can vary over time, there are several notable players in the field. Some competitors that are worth considering include:

GlaxoSmithKline (GSK): A global pharmaceutical company involved in vaccine development and research.
AstraZeneca Plc (AZN): A multinational pharmaceutical company with a broad portfolio of medicines and vaccines.
Moderna Inc. (MRNA): A biotechnology company known for its mRNA-based vaccine technology.
Pfizer Inc. (PFE): A leading pharmaceutical company engaged in the development and commercialization of vaccines and medicines.

It is important to conduct thorough research and analysis of the competitive landscape, considering factors such as product pipeline, market position, financial performance, and regulatory approvals, to make informed trading decisions regarding Bavarian Nordic AS stock.

Premium Standard

Swap long	[[ data.swapLong ]] points
Swap short	[[ data.swapShort ]] points
Spread min	[[ data.stats.minSpread ]]
Spread avg	[[ data.stats.avgSpread ]]
Min contract size	[[ data.minVolume ]]
Min step size	[[ data.stepVolume ]]
Commission and Swap	Commission and Swap
Leverage	Leverage
Trading Hours	Trading Hours

* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.

The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.

Trade Now

Trade [[data.name]] with Skilling

All Hassle-free, with flexible trade sizes and with zero commissions!*

Trade 24/5
Minimum margin requirements
No commission, only spread
Fractional shares available
Easy to use platform

*Other fees may apply.

FAQs

What are the key drivers affecting Bavarian Nordic AS's stock price?

+ -

Bavarian Nordic AS (BAVAc.DXE) is influenced by several key drivers that could impact its stock price. One important factor is the company's pipeline of vaccines and immunotherapies, as positive clinical trial results or regulatory approvals could boost traders’ confidence and potentially drive the stock price higher. Additionally, market trends and sentiment towards the biotechnology industry could play a role in determining the stock's valuation.

Factors such as competition, changes in healthcare policies, and global health crises may also affect the stock price of the stock. It is crucial for traders to consider these factors and stay updated with the latest news and developments in the healthcare sector to make informed trading decisions.

Who owns the majority of Bavarian Nordic AS shares?

+ -

As of June 30th 2023, the top shareholders and their corresponding holdings include:

1. Invesco Global Opportunities Fund: 2,880,000 shares (3.70%).
2. Vanguard International Stock Index-Total Intl Stock Index: 928,818 shares (1.19%).
3. Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund: 618,645 shares (0.79%).
4. DFA Continental Small Company Series: 448,836 shares (0.58%).
5. iShares Core MSCI EAFE ETF: 436,394 shares (0.56%).
6. DFA International Core Equity Portfolio: 338,191 shares (0.43%).
7. iShares MSCI EAFE Small Cap ETF: 331,009 shares (0.42%).
8. Victory Portfolios-Victory Trivalent International Small Cap Fund: 291,522 shares (0.37%).
9. Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Small Cap Index: 270,560 shares (0.35%).
10. Vanguard International Stock Index-Vanguard European Stock Index: 149,284 shares (0.19%).

Do Bavarian Nordic AS shares pay dividends?

+ -

Bavarian Nordic AS does not currently pay dividends to its shareholders (as of September 2023). The company's focus is primarily on research, development, and commercialization of vaccines and immunotherapies, which means that profits are typically reinvested back into the business for future growth.

Traders often evaluate the company's stock performance based on factors such as revenue growth, clinical trial results, partnerships, and potential market opportunities. It is essential for traders to analyze various indicators and stay informed about company announcements and developments to make informed trading decisions.

Why Trade [[data.name]]

Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.